These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1525057)

  • 1. Inhibition of oestrogen synthesis in postmenopausal women with breast cancer.
    James VH; Reed MJ; Purohit A
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):149-53. PubMed ID: 1525057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates.
    Woo LL; Purohit A; Malini B; Reed MJ; Potter BV
    Chem Biol; 2000 Oct; 7(10):773-91. PubMed ID: 11033081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
    Johannessen DC; Adlercreutz H; Fotsis T; Lønning PE
    Br J Cancer; 1993 Aug; 68(2):393-8. PubMed ID: 8135918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
    Dowsett M; Stein RC; Coombes RC
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):155-9. PubMed ID: 1388047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues.
    Reed MJ; Aherne GW; Ghilchik MW; Patel S; Chakraborty J
    Int J Cancer; 1991 Oct; 49(4):562-5. PubMed ID: 1917157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of aromatase in breast tumors.
    Reed MJ
    Breast Cancer Res Treat; 1994; 30(1):7-17. PubMed ID: 7949206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of breast cyst fluid on oestrone sulphatase activity in MCF-7 breast cancer cells.
    Erbas H; Lennard TW; Lai LC
    Anticancer Res; 1996; 16(2):833-6. PubMed ID: 8687137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
    MacNeill FA; Jacobs S; Lønning PE; Powles TJ; Dowsett M
    Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate.
    Purohit A; Williams GJ; Roberts CJ; Potter BV; Reed MJ
    Int J Cancer; 1995 Sep; 63(1):106-11. PubMed ID: 7558436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione.
    Reed MJ; Owen AM; Lai LC; Coldham NG; Ghilchik MW; Shaikh NA; James VH
    Int J Cancer; 1989 Aug; 44(2):233-7. PubMed ID: 2759729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of tissue oestradiol levels in human breast cancer.
    Santen RJ
    Cancer Surv; 1986; 5(3):597-616. PubMed ID: 3555785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of steroid sulphatase activity by steroidal methylthiophosphonates: potential therapeutic agents in breast cancer.
    Purohit A; Howarth NM; Potter BV; Reed MJ
    J Steroid Biochem Mol Biol; 1994 Apr; 48(5-6):523-7. PubMed ID: 8180114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control and expression of oestrone sulphatase activities in human breast cancer.
    Pasqualini JR; Chetrite G; Nestour EL
    J Endocrinol; 1996 Sep; 150 Suppl():S99-105. PubMed ID: 8943793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The origin of oestrone sulphate in normal and malignant breast tissues in postmenopausal women.
    Purohit A; Riaz AA; Ghilchik MW; Reed MJ
    Horm Metab Res; 1992 Nov; 24(11):532-6. PubMed ID: 1452119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
    Reed MJ; Lai LC; Owen AM; Singh A; Coldham NG; Purohit A; Ghilchik MW; Shaikh NA; James VH
    Cancer Res; 1990 Jan; 50(1):193-6. PubMed ID: 2293555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity.
    Purohit A; Vernon KA; Hummelinck AE; Woo LW; Hejaz HA; Potter BV; Reed MJ
    J Steroid Biochem Mol Biol; 1998 Mar; 64(5-6):269-75. PubMed ID: 9618028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
    Jones AL; MacNeill F; Jacobs S; Lonning PE; Dowsett M; Powles TJ
    Eur J Cancer; 1992; 28A(10):1712-6. PubMed ID: 1389491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
    Lombardi P
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):326-37. PubMed ID: 12084475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
    Lønning PE; Dowsett M; Jones A; Ekse D; Jacobs S; McNeil F; Johannessen DC; Powles TJ
    Breast Cancer Res Treat; 1992; 23(1-2):57-62. PubMed ID: 1446052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
    Geisler J; Johannessen DC; Anker G; Lønning PE
    Eur J Cancer; 1996 May; 32A(5):789-92. PubMed ID: 9081355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.